Elevated CD21 low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency

• Published in: Journal of clinical immunology 2022-05, Vol.42 (4), p.716
• Main Authors: Bergman, Peter, Wullimann, David, Gao, Yu, Wahren Borgström, Emilie, Norlin, Anna-Carin, Lind Enoksson, Sara, Aleman, Soo, Ljunggren, Hans-Gustaf, Buggert, Marcus, Smith, C I Edvard
• Format: Article
• Language: English
• Subjects: Antibodies, Viral; BNT162 Vaccine; Common Variable Immunodeficiency; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; mRNA Vaccines; Prospective Studies; SARS-CoV-2; Vaccines, Synthetic
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1007/s10875-022-01244-2

Limited data is available on the effect of COVID-19 vaccination in immunocompromised individuals. Here, we provide the results from vaccinating a single-center cohort of patients with common variable immunodeficiency (CVID). In a prospective, open-label clinical trial, 50 patients with CVID and 90 age-matched healthy controls (HC) were analyzed for SARS-CoV-2 spike antibody (Ab) production after one or two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine. Additionally, in selected patients, SARS-CoV-2 spike-specific T-cells were assessed. A potent vaccine-induced anti-spike-specific IgG Ab response was observed in all the HC. In contrast, only 68.3% of the CVID patients seroconverted, with median titers of specific Ab being 83-fold lower than in HC. In fact, only 4/46 patients (8.6%) of patients who were seronegative at baseline reached the threshold for an optimal response (250 U/mL). Using the EUROclass definition, patients with either a reduced proportion, but not absolute counts, of switched memory B-cells or having an increased frequency of CD21 B-cells generally generated poor vaccine responses. Overall, CVID-patients had reduced spike-specific IFN-γ positive CD4 T cell responses 2 weeks after the second dose, compared to HC. The total CD4 and CD4 central memory cell counts correlated with humoral immunity to the vaccine. CVID patients with low frequency of switched memory B-cells or an increased frequency of CD21 B-cells according to the EUROclass definition demonstrated poor responses to Pfizer-BioNTech BNT162b2 mRNA vaccination. Cellular immune responses were significantly affected, affirming that the defect in CVID is not limited to humoral immunity.